Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects
- PMID: 19224107
- DOI: 10.1007/s00406-009-0868-5
Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects
Abstract
Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB(1)) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of motor activity. Based on the close relationship between cannabis use, the endogenous cannabinoid system and motor disturbances found in schizophrenia, we expected that administration of cannabinoids may change pattern of psychomotor activity like in schizophrenic patients. This prospective, double-blind, placebo-controlled cross-over study investigated the acute effects of cannabinoids on psychomotor performance in 24 healthy right-handed volunteers (age 27.9 +/- 2.9 years, 12 male) by comparing Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and standardized cannabis extract containing Delta(9)-THC and cannabidiol. Psychomotor performance was assessed by using a finger tapping test series. Cannabis extract, but not Delta(9)-THC, revealed a significant reduction of right-hand tapping frequencies that was also found in schizophrenia. As to the pure Delta(9)-THC condition, left-hand tapping frequencies were correlated with the plasma concentrations of the Delta(9)-THC metabolite 11-OH-THC. These effects are thought to be related to cannabinoid actions on CB(1) receptors in the basal ganglia, the cerebral cortex and the cerebellum. Our data further demonstrate that acute CB(1) receptor activation under the cannabis extract condition may also affect intermanual coordination (IMC) as an index of interhemispheric transfer. AIR-Scale scores as a measure of subjective perception of intoxication were dose-dependently related to IMC which was shown by an inverted U-curve. This result may be due to functional changes involving GABAergic and glutamatergic neurotransmission within the corpus callosum.
Similar articles
-
The Pharmacokinetics and Pharmacodynamics of a Hemp-Derived "Full-Spectrum" Oral Cannabinoid Product with a 1:1 Ratio of Cannabidiol to Cannabidiolic Acid and Delta-9-Tetrahydrocannabinol to Delta-9-Tetrahydrocannabinolic Acid: A Double-Blind, Placebo-Controlled, Within-Subjects Human Laboratory Study.Cannabis Cannabinoid Res. 2025 Apr;10(2):e299-e313. doi: 10.1089/can.2024.0187. Epub 2025 Mar 5. Cannabis Cannabinoid Res. 2025. PMID: 40040421 Clinical Trial.
-
Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.J Anal Toxicol. 2005 Jul-Aug;29(5):327-38. doi: 10.1093/jat/29.5.327. J Anal Toxicol. 2005. PMID: 16105257 Clinical Trial.
-
A within-subject cross-over trial comparing the acute effects of oral delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in healthy adults.Drug Alcohol Depend. 2025 Jul 1;272:112676. doi: 10.1016/j.drugalcdep.2025.112676. Epub 2025 Apr 12. Drug Alcohol Depend. 2025. PMID: 40288059 Clinical Trial.
-
Neuromolecular Mechanisms of Cannabis Action.Adv Exp Med Biol. 2021;1264:15-28. doi: 10.1007/978-3-030-57369-0_2. Adv Exp Med Biol. 2021. PMID: 33332001 Review.
-
Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.Curr Pharm Des. 2012;18(32):4966-79. doi: 10.2174/138161212802884780. Curr Pharm Des. 2012. PMID: 22716148 Review.
Cited by
-
Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence.Cannabis Cannabinoid Res. 2020 Sep 2;5(3):191-196. doi: 10.1089/can.2019.0052. eCollection 2020. Cannabis Cannabinoid Res. 2020. PMID: 32923656 Free PMC article. Review.
-
Altered brain activation during visuomotor integration in chronic active cannabis users: relationship to cortisol levels.J Neurosci. 2011 Dec 7;31(49):17923-31. doi: 10.1523/JNEUROSCI.4148-11.2011. J Neurosci. 2011. PMID: 22159107 Free PMC article.
-
Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults.Psychopharmacology (Berl). 2020 Feb;237(2):305-316. doi: 10.1007/s00213-019-05369-y. Epub 2019 Oct 22. Psychopharmacology (Berl). 2020. PMID: 31637452 Clinical Trial.
-
Neurological soft signs in Tunisian patients with first-episode psychosis and relation with cannabis use.Ann Gen Psychiatry. 2017 Jul 12;16:30. doi: 10.1186/s12991-017-0153-3. eCollection 2017. Ann Gen Psychiatry. 2017. PMID: 28717382 Free PMC article.
-
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.Br J Pharmacol. 2015 Feb;172(3):737-53. doi: 10.1111/bph.12944. Br J Pharmacol. 2015. PMID: 25257544 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials